ArriVent BioPharma, Inc. Common Stock (AVBP)vsMerck & Company Inc (MRK)
AVBP
ArriVent BioPharma, Inc. Common Stock
$24.89
+2.77%
HEALTHCARE · Cap: $1.10B
MRK
Merck & Company Inc
$120.87
+0.02%
HEALTHCARE · Cap: $298.76B
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
AVBP
Avoid26
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVBP.
Margin of Safety
-144.5%
Fair Value
$49.44
Current Price
$120.87
$71.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AVBP carries more volatility with a beta of 1.00 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 26/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. is a specialized biopharmaceutical company committed to advancing innovative therapies aimed at addressing unmet medical needs in oncology and autoimmune disorders. Leveraging proprietary technologies and a solid scientific foundation, the company is developing a diverse pipeline of potential treatment candidates designed to significantly improve patient outcomes. With a strategic emphasis on high-growth sectors within the biopharma industry, ArriVent presents a compelling investment opportunity for institutional investors seeking exposure to transformative healthcare advancements.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?